



Beesley, J., Kar, S., Edwards, S. L., & French, J. D. (2020). eQTL Colocalization Analyses Identify NTN4 as a Candidate Breast Cancer Risk Gene. *American Journal of Human Genetics*, (2020).
<https://doi.org/10.1016/j.ajhg.2020.08.006>

Peer reviewed version

Link to published version (if available):
[10.1016/j.ajhg.2020.08.006](https://doi.org/10.1016/j.ajhg.2020.08.006)

[Link to publication record in Explore Bristol Research](#)
PDF-document

This is the author accepted manuscript (AAM). The final published version (version of record) is available online via Cell Press at <https://doi.org/10.1016/j.ajhg.2020.08.006> . Please refer to any applicable terms of use of the publisher.

University of Bristol - Explore Bristol Research

General rights

This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available:
<http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/>

1 **eQTL colocalization analyses identify *NTN4* as a candidate breast cancer risk gene**

2

3 Jonathan Beesley^{1*#}, Haran Sivakumaran^{1*}, Mahdi Moradi Marjaneh^{1,2*}, Wei Shi¹, Kristine M
4 Hillman¹, Susanne Kaufmann¹, Nehal Hussein^{1,3}, Siddhartha Kar⁴, Luize G Lima¹, Sunyoung Ham¹,
5 Andreas Möller^{1,3}, Georgia Chenevix-Trench^{1*}, Stacey L Edwards^{1*#}, Juliet D French^{1*}

6

7

8 ¹ Cancer Division, QIMR Berghofer Medical Research Institute, Brisbane, 4029, Australia.

9 ² Present address: UK Dementia Research Institute, Imperial College London, W12 0BZ, UK.

10 ³ Faculty of Medicine, The University of Queensland, Brisbane, 4006, Australia.

11 ⁴ MRC Integrative Epidemiology Unit, University of Bristol, Bristol, UK; Population Health Sciences,
12 Bristol Medical School, University of Bristol, Bristol, UK.

13 * These authors jointly contributed.

14

15 # Correspondence: Jonathan.Beesley@qimrberghofer.edu.au

16 Stacey.Edwards@qimrberghofer.edu.au

17

18

19 **ABSTRACT**

20 Breast cancer genome-wide association studies (GWAS) have identified 150 genomic risk regions
21 containing more than 13,000 credible causal variants (CCVs). The CCVs are predominantly
22 noncoding and enriched in regulatory elements. However, the genes underlying breast cancer risk
23 associations are largely unknown. Here, we used genetic colocalization analysis to identify loci at
24 which gene expression could potentially explain breast cancer risk phenotypes. Using data from the
25 Breast Cancer Association Consortium (BCAC) and quantitative trait loci (QTL) from the Genotype-
26 Tissue Expression (GTEx) project and The Cancer Genome Project (TCGA), we identify shared
27 genetic relationships and reveal novel associations between cancer phenotypes and effector genes.
28 Seventeen genes, including *NTN4*, were identified as potential mediators of breast cancer risk. For
29 *NTN4*, we showed the rs61938093 CCV at this region was located within an enhancer element that
30 physically interacts with the *NTN4* promoter, and the risk allele reduced *NTN4* promoter activity.
31 Furthermore, knockdown of *NTN4* in breast cells increased cell proliferation *in vitro* and tumor growth
32 *in vivo*. These data provide evidence linking risk-associated variation to genes that may contribute
33 to breast cancer predisposition.

34

35

36 The influence of common genetic variation on gene expression underlies a considerable proportion
37 of the heritability associated with complex traits. Mapping of expression QTL (eQTL), where genetic
38 variants are tested for association with gene expression levels, is widely used to identify genes that
39 are regulated by trait-associated variants. Several studies have shown that eQTLs are enriched in
40 cell types relevant to the trait of interest^{1, 2}. For example, T cell-specific eQTLs are over-represented
41 for autoimmune risk alleles and monocyte-specific eQTLs for Alzheimer's [MIM: 104300] and
42 Parkinson's [MIM: 168600] disease alleles². For breast cancer [MIM: 114480], several studies have
43 used eQTL data from tumor and normal tissues datasets to identify candidate target genes³⁻⁶. Recent
44 studies have also showed that breast cancer risk variants could regulate genes in cells of the tumor
45 microenvironment, such as immune cells and fibroblasts^{7, 8}. Because eQTLs are widespread, overlap
46 between GWAS and eQTL signals is likely to occur by chance when using nominal significance

47 levels. To mitigate false positive findings it is therefore important to show that the same genetic
48 signal underlies gene expression and disease susceptibility.

49

50 Several statistical colocalization approaches have been developed to determine whether molecular
51 traits (e.g. gene expression) and a disease trait share common causal variants. The simplest
52 Bayesian model used in tools such as QTLMatch⁹ and COLOC¹⁰ tests for colocalization for two traits
53 and determines whether they are driven by distinct variants or share a single causal signal. For
54 example, Parker et al used COLOC to identify 32 emphysema-associated [MIM: 130700] regions
55 where it is likely that colocalized GWAS and eQTL signals arise from the same causal variant¹¹.
56 Additional functional studies then showed that the emphysema-associated variant rs1690789
57 regulates *TGFB2* (encoding transforming growth factor beta 2 [MIM: 190220]) expression in human
58 lung fibroblasts. A recent implementation of COLOC, called HyPrColoc (Hypothesis Prioritization in
59 multi-trait Colocalization), identifies colocalized association signals using summary statistics on large
60 number of traits¹². This method has been used to identify regulatory loci underlying quantitative
61 haematopoietic traits¹³.

62

63 In this study, we extracted eQTL association effect estimates and standard errors for all variants at
64 the 150 breast cancer risk loci previously analysed by BCAC¹⁴ (mean region size = 1.09 Mb). GWAS
65 summary data were available for overall breast cancer risk from 122,977 cases and 105,974
66 controls³; and for estrogen receptor negative (ER-) breast cancer risk from 21,468 cases and
67 100,594 controls, combined with 18,908 *BRCA1* mutation carriers (9414 with breast cancer)¹⁵ all of
68 European ancestries. Variant IDs were converted to GRCH38 build co-ordinates and harmonized
69 with GTEx data (0.86% failed conversion and were dropped from the analysis). The GTEx version 8
70 release includes data from normal breast tissue from 396 individuals. GTEx eQTL association data
71 for variants within ± 1 Mb windows of transcription start sites were extracted based on the variants
72 present in the breast cancer risk data. Colocalization of the GWAS and eQTL signals were calculated
73 using the HyPrColoc R package¹². Breast cancer risk phenotypes and each proximal gene were
74 analyzed separately with default parameters. Signals were considered to be plausibly colocalizing if
75 posterior probability for colocalization (PPFC) > 0.7 , resulting in a false discovery rate of 5%¹².

76

77 We identified 17 genes at 14 loci where the GTEx eQTL association P values are $< 10^{-6}$ (**Table 1**).
78 For every locus, all candidate SNPs met the GWAS significance P value threshold (5×10^{-8}) for overall
79 or ER- breast cancer risk (**Table 1**). For 11 loci (*NTN4*, *PIDD1* [MIM: 605247], *CBX8* [MIM: 617354],
80 *L3MBTL3* [MIM: 618844], *RCCD1* [MIM: 617997], *PRC1-AS1*, *SSBP4* [MIM: 607391], *MARCH11*
81 [MIM: 613338], *ZNF596*, *RP5-855D21.3* and *RP11-53O19.1*), the candidate colocalized SNPs have
82 been previously nominated as strong candidate causal signals using multivariate logistic
83 regression¹⁴ (**Table 1** and **Figure 1**). However, at six loci (*ATG10* [MIM: 610800], *CCDC88C* [MIM:
84 611204], *PPM1K* [MIM: 611065], *RP11-250B2.3*, *RP1-265C24.5* and *RP11-250B2.5*), the
85 colocalized signals are independent secondary signals based on stepwise multinomial logistic
86 regression analysis ($10^{-6} < P < 10^{-4}$)¹⁴. While this does not rule out causality, larger GWAS would
87 be required to confirm genome-wide significance (**Figure S1**)¹⁴.

88

89 Published computational predictions of target genes at breast cancer risk loci using the INQUISIT
90 pipeline (which interrogates data including ChIA-PET, Hi-C, ChIP-seq and eQTL data independent
91 of GTEx) provide further support for ten colocalized genes (**Table S1**)^{3, 14}. Of these, *NTN4*, *PIDD1*,
92 *L3MBTL3* and *RCCD1* have the strongest evidence from functional genomics data. Transcriptome-
93 wide association studies also suggest that 13 of the 17 genes are regulated by breast cancer risk
94 variants^{5-7, 16, 17} (**Table S1**). Moreover, previous eQTL analysis based on TCGA breast tumor data
95 have identified three of these candidate genes^{3, 14} (**Figure S2**). For three genes (*PIDD1*, *L3MBTL3*
96 and *SSBP4*), CCVs are located in the promoter regions, and for *PIDD1* previous reporter assays
97 indicate the risk haplotype increases promoter activity³. Our recent capture Hi-C data showed also
98 chromatin looping occurs between putative regulatory regions containing CCVs and the promoters
99 of four genes (*NTN4*, *PRC1-AS1*, *ATG10* and *RP1-265C24.5*) in breast cell lines¹⁸. For the remaining
100 loci, multiple CCVs were located in the introns of target genes and/or intergenic regions, but lacked
101 demonstrable CCV-gene interactions. It is possible that some *cis*-regulatory interactions are only
102 detected in specific breast cell subpopulations, or that CCVs are acting through other mechanisms
103 such as perturbation of pre-messenger RNA splicing or altered noncoding RNA stability, structure
104 and/or function. Of note, three genes (*PIDD1*, *CBX8*, and *L3MBTL3*) contain breast cancer CCVs in

105 their exons which are predicted to change the amino acid sequence, thus we cannot rule out that
106 these are functional variants that affect the protein product.

107

108 One high probability colocalization signal, targeting *NTN4*, was detected at a locus at 12q22 (**Table**
109 **1, Figures 1 and 2**). Genetic fine-mapping studies have identified one risk signal at 12q22 that
110 contains two CCVs (rs61938093 and rs17356907; odds ratio = 1.094, $r_2 = 1$)¹⁴. Both CCVs fall within
111 putative regulatory elements (PREs) marked by open chromatin in B80T5 and MCF10A non-
112 tumorigenic breast cell lines (**Figure 3A**). The PREs map to a large intergenic region between
113 *USP44* [MIM: 610993] (encoding ubiquitin-specific protease 44) and *NTN4* (encoding Netrin 4;
114 **Figure 3A**). Using promoter capture HiC data¹⁸, we observed that the PREs frequently participate in
115 long-range chromatin interactions with the *NTN4* promoter in non-tumorigenic and tumorigenic
116 breast cell lines (**Figures 3A and S2A**). Notably, no other eQTLs or chromatin interactions from the
117 PRE to promoter regions were detected in the breast cell lines we examined (**Figures 3A and**
118 **S2A**)¹⁸, suggesting *NTN4* is the likely target gene at this signal.

119

120 To determine how the PRE alters *NTN4* transcriptional activity, we targeted a nuclease-defective
121 dCas9 fused to the Kruppel-associated box (lentiviral vector pHR-SFFV-dCas9-BFP-KRAB; a gift
122 from Stanley Qi & Jonathan Weissman, Addgene plasmid #46911) to the PRE. Two independent
123 single-guide RNAs (sgRNAs) targeting the PRE were designed (**Table S2**) and cloned into the
124 lentiviral vector pgRNA-humanized (a gift from Stanley Qi, Addgene plasmid #44248). Lentiviral
125 particles were produced from HEK293 cells transfected with accessory plasmids pCMV-dR8.91 and
126 pCMV-VSV-G (gifts from David Harrich, QIMR Berghofer), and with dCas9-KRAB or pgRNA
127 constructs using Lipofectamine 2000 (Life Technologies). Supernatants from dCas9-KRAB and
128 pgRNA cultures were mixed and transduced into Bre80-TERT1 breast cells. Cells expressing both
129 dCas9-KRAB (co-expressing blue fluorescent protein) and pgRNA (co-expressing mCherry) were
130 enriched by FACS on the Aria IIIu platform (Becton-Dickinson). Notably, silencing of the PRE
131 significantly reduced *NTN4* expression in Bre80-TERT1 cells, suggesting that the PRE acts as an
132 transcriptional enhancer (**Figure 3B**).

133

134 The regulatory capability of the PRE, combined with the effects of the CCVs, was further examined
135 in reporter assays. An *NTN4* promoter-driven luciferase reporter construct was generated by the
136 insertion of a PCR amplified genomic fragment into the KpnI/HindIII sites of pGL3-basic (Promega).
137 A 1010 base pairs (bp) fragment containing a PRE1, with either the risk or protective alleles of
138 rs61938093, or a 983 bp fragment containing a PRE2, with either the risk or protective alleles of
139 rs17356907, were synthesized as gBlocks (Integrated DNA Technologies) and then cloned into the
140 BamHI/Sall sites of the *NTN4*-promoter construct (genomic coordinates and primers are listed in
141 **Table S2**). MCF10A and Bre80-TERT1 breast cells were transfected with the reporter constructs
142 and luciferase activity was measured 24 h post-transfection using the Dual-Glo Luciferase System
143 (Promega). To correct for any differences in transfection efficiency, *Firefly* luciferase activity was
144 normalized to *Renilla*. Reporter assays confirmed strong enhancer activity of the PRE1 on the *NTN4*
145 promoter in MCF10A and Bre80-TERT1 cells and inclusion of the rs6198093 risk allele significantly
146 reduced *NTN4* promoter activity (**Figure 3C**). In contrast, inclusion of PRE2 with the protective or
147 risk alleles of rs17356907 had no significant effects on the *NTN4* promoter activity. pGL3-promoter
148 luciferase results ????? These results suggest that rs61938093 alters transactivation of *NTN4*, but it
149 is possible that the CCVs also influence recruitment of key proteins required for chromatin looping
150 between the enhancer and *NTN4* promoter, which would not be observed in a reporter assay.

151

152 To assess the potential impact of the CCVs on chromatin looping, quantitative allele-specific 3C was
153 performed in heterozygous MCF10A and T47D breast cell lines. 3C libraries were generated using
154 HindIII as previously described¹⁹. Three independent 3C libraries or genomic input DNA were
155 amplified for 15 cycles with two separate xxxxx 3C specific or genomic DNA PCR primers (primers
156 are listed in **Table S2**) and purified by QIAGEN columns. Allele-specific PCR products were then
157 quantified using a custom TaqMan SNP genotyping assay for rs61938093 (Life Technologies) on
158 the Rotor-Gene 6000 platform. Purified PCR products were Sanger sequenced by the Australian
159 Genome Research Facility (AGRF). The results showed a preference for the protective *t*-allele
160 (**Figures 3D, 3E and S2B-S2E**), indicating that risk alleles may abrogate looping between the
161 enhancer and *NTN4* which in turn may reduce *NTN4* expression.

162

163 Electrophoretic mobility shift assays (EMSAs) then assessed transcription factor (TF) binding for the
164 protective and risk alleles of the CCVs. Nuclear lysates were prepared from Bre80-TERT1 and
165 MCF10A breast cells using the NE-PER nuclear and cytoplasmic protein extraction kit
166 (ThermoFisher). Biotinylated oligonucleotides representing either the risk or protective allele were
167 synthesized (Integrated DNA Technologies; **Table S2**) and annealed to form double-stranded
168 duplexes. Duplex-bound complexes were resolved by electrophoresis in 10% (w/v) Tris-borate-
169 EDTA polyacrylamide (Lonza) and transferred to positively-charged nylon membranes by semi-dry
170 transfer (Bio-Rad). Membranes were processed using the LightShift Chemiluminescent EMSA kit
171 (ThermoFisher) and visualized with the C-DiGit blot scanner. The EMSAs showed that rs61938093
172 and rs17356907 altered protein binding *in vitro* in Bre80-TERT1 and MCF10A cell lysates (**Figures**
173 **3F**, **S3A** and **S3B**). *In silico* prediction tools including HaploReg²⁰ and Alibaba²²¹ predicted both
174 CCVs to alter TF binding. However, EMSAs using competitor DNA against predicted and other
175 breast-relevant TFs were unable to identify the specific protein(s) binding to the alleles (**Figures**
176 **S3C** and **S3D**).

177
178 We examined expression of *NTN4* in matched normal and cancerous breast tissues using TCGA
179 RNA-seq data. *NTN4* was more highly expressed in normal tissue, a mixture of cell types, compared
180 to adjacent tumor samples (**Figure 4A**) and is expressed across the histological subtypes, albeit
181 with lower expression in the basal subtype (**Figure 4B**). To explore the effect of reduced *NTN4* on
182 breast cancer cell proliferation, MCF7 cells were transfected with ON-TARGETplus negative control
183 or *NTN4* siRNA smartpools (Dharmacon) using RNAiMAX (Life Technologies). *NTN4* silencing was
184 confirmed by TaqMan qPCR gene expression assay 72 h post-transfection (**Figures S3E** and **S3F**).
185 Notably, *NTN4* depletion promoted anchorage-dependent and -independent cell growth in MCF7
186 cells (**Figures 4C** and **4D**). To assess the effect of reduced *NTN4* on tumor growth, we stably
187 depleted *NTN4* in MCF7 cells by targeting dCAS9-KRAB to the promoter of *NTN4*, and injected the
188 cells in the mammary fat pad of nude mice. Female BALB/c-Foxn1^{nu}/Arc mice were first
189 subcutaneously implanted with 17 β -estradiol (0.72 mg/pellet, 90 day release; Innovative Research
190 of America) at 8 weeks of age. MCF7 control-CRISPRi or *NTN4*-CRISPRi cells were orthotopically
191 injected into mammary fatpads 3 days later at 10⁷ cells per mouse (6-7 mice per cell line). Tumor

192 volumes were measured every 2 days until experimental end, at which point mice were euthanized
193 and their tumors excised and weighed. All animal procedures were conducted in accordance with
194 Australian National Health and Medical Research regulations on the use and care of experimental
195 animals, and approved by the QIMR Berghofer Medical Research Institute Animal Ethics Committee
196 (P1499). Compared to control MCF7 cells containing non-targeting sgRNA, *NTN4* depletion led to a
197 marked increase in tumor growth (**Figures 4E, 4F and S3G**), which was reflected in increased tumor
198 weight (**Figure 4G**).

199
200 *NTN4* encodes the Netrin-4 secreted protein which has been implicated in various developmental
201 processes including axon guidance, angiogenesis, mammary and lung morphogenesis²². Several
202 studies show that *NTN4* is involved in cancer, but the exact role of *NTN4* appears to be dependent
203 on the cancer type. For example, *NTN4* knockdown reduces cell proliferation and motility in gastric
204 cancer [MIM: 613659] and melanoma [MIM: 155600]^{23; 24}, but promotes cell migration and invasion
205 in colorectal cancer [MIM: 114500] and breast cancer^{25; 26}. *NTN4* has also been implicated in breast
206 cancer progression. For example, reduced *NTN4* is reported to promote migration and invasion of
207 breast cancer cells through epithelial to mesenchymal transition²⁶. In addition, *NTN4* has been
208 shown to be an independent biomarker for prognosis of survival in breast cancer^{27; 28}. We and others
209 have demonstrated that SNPs can alter chromatin loop formation between promoters and
210 enhancers^{29; 30}. Here, we provide evidence that the same mechanism may explain how breast cancer
211 CCVs alter *NTN4* expression and that suppressed *NTN4* increases cancer-related processes
212 including cell proliferation and tumor growth. However, we acknowledge that further functional
213 studies will be required to clarify how *NTN4* contributes to breast tumor initiation.

214
215 Seven additional colocalized target genes have prior evidence for a functional role in cancer. For
216 example, *PIDD1* (p53-induced death domain protein 1) is implicated in DNA-damage-induced
217 apoptosis and tumorigenesis³¹. *CBX8* is overexpressed in breast cancer and correlates with poor
218 survival³². *CBX8* functions by interacting with the H3K4 methyltransferase complex component
219 *WDR5* to activate genes involved in Notch signaling and promote breast tumorigenesis³².
220 Furthermore, Guo et al showed ectopic *ATG10* (autophagy related 10) overexpression decreases

221 colony formation of MDA-MB-231 breast cancer cells, suggesting it may play a role in breast
222 tumorigenesis⁵. Notably, ten genes have no reported involvement in breast tumorigenesis and may
223 represent new genes that influence the susceptibility to breast cancer. This list includes five lncRNAs
224 which are arguably more challenging to investigate as they can have multiple functions. However,
225 there is increasing evidence that dysregulated lncRNAs contribute to breast cancer etiology^{29; 33; 34}.

226

227 In summary, we used eQTL colocalization to link breast cancer risk variants to seventeen target
228 genes, including some potential cancer driver genes, but many with no reported role in breast cancer
229 etiology. However, even with demonstration of shared genetic signals, it is as yet unknown how
230 genes implicated by statistical colocalization analyses reflect true molecular mechanisms. It is
231 therefore important to perform functional assays, as we have done for *NTN4*, to provide evidence
232 that the variant affects gene expression and the gene plays a role in the disease etiology. Future
233 work confirming the role of these genes or associated pathways in breast cancer development could
234 ultimately lead to new avenues for breast cancer prevention or therapy.

235

236 **SUPPLEMENTAL DATA**

237 Supplemental Data include three figures and two tables.

238

239 **ACKNOWLEDGEMENTS**

240 This work was supported by a grant from the National Health and Medical Research Council of
241 Australia (NHMRC; 1120563). S.L.E. is an NHMRC Senior Research Fellow (1135932). G.C.T is an
242 NHMRC Senior Principal Research Fellow (1117073). J.D.F was supported by a Fellowship from
243 the National Breast Cancer Foundation of Australia. N.A. was co-funded by a QIMR Berghofer
244 International PhD Scholarship and a University of Queensland Research Training Scholarship. The
245 results published here are in part based upon data generated by the TCGA Research Network. The
246 breast cancer genome-wide association analyses were supported by the Government of Canada
247 through Genome Canada and the Canadian Institutes of Health Research, the 'Ministère de
248 l'Économie, de la Science et de l'Innovation du Québec' through Genome Québec and grant PSR-
249 SIIRI-701, The National Institutes of Health (U19 CA148065, X01HG007492), Cancer Research UK

250 (C1287/A10118, C1287/A16563, C1287/A10710) and The European Union (HEALTH-F2-2009-
251 223175 and H2020 633784 and 634935). All studies and funders are listed in 3.

252

253 **DECLARATION OF INTERESTS**

254 The authors declare no conflict of interests.

255

256 **WEB RESOURCES**

257 Breast Cancer Association Consortium,

258 [http://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/gwas-icogs-and-oncoarray-summary-
259 results/](http://bcac.ccge.medschl.cam.ac.uk/bcacdata/oncoarray/gwas-icogs-and-oncoarray-summary-
259 results/)

260 GTEx Portal, <https://gtexportal.org/home/>

261 LDlink, <https://ldlink.nci.nih.gov/>

262 Bioconductor, <https://www.bioconductor.org/>

263

264 **REFERENCES**

265 1. Ongen, H., Brown, A.A., Delaneau, O., Panousis, N.I., Nica, A.C., Consortium, G.T., and
266 Dermitzakis, E.T. (2017). Estimating the causal tissues for complex traits and diseases. *Nat*
267 *Genet* 49, 1676-1683.

268 2. Raj, T., Rothamel, K., Mostafavi, S., Ye, C., Lee, M.N., Replogle, J.M., Feng, T., Lee, M.,
269 Asinovski, N., Frohlich, I., et al. (2014). Polarization of the effects of autoimmune and
270 neurodegenerative risk alleles in leukocytes. *Science* 344, 519-523.

271 3. Michailidou, K., Lindstrom, S., Dennis, J., Beesley, J., Hui, S., Kar, S., Lemacon, A., Soucy, P.,
272 Glubb, D., Rostamianfar, A., et al. (2017). Association analysis identifies 65 new breast
273 cancer risk loci. *Nature* 551, 92-94.

274 4. Li, Q., Seo, J.H., Stranger, B., McKenna, A., Pe'er, I., Laframboise, T., Brown, M., Tyekuceva,
275 S., and Freedman, M.L. (2013). Integrative eQTL-based analyses reveal the biology of breast
276 cancer risk loci. *Cell* 152, 633-641.

277 5. Guo, X., Lin, W., Bao, J., Cai, Q., Pan, X., Bai, M., Yuan, Y., Shi, J., Sun, Y., Han, M.R., et al.
278 (2018). A Comprehensive cis-eQTL Analysis Revealed Target Genes in Breast Cancer

- 279 Susceptibility Loci Identified in Genome-wide Association Studies. *Am J Hum Genet* 102,
280 890-903.
- 281 6. Wu, L., Shi, W., Long, J., Guo, X., Michailidou, K., Beesley, J., Bolla, M.K., Shu, X.O., Lu, Y., Cai,
282 Q., et al. (2018). A transcriptome-wide association study of 229,000 women identifies new
283 candidate susceptibility genes for breast cancer. *Nat Genet* 50, 968-978.
- 284 7. Ferreira, M.A., Gamazon, E.R., Al-Ejeh, F., Aittomaki, K., Andrulis, I.L., Anton-Culver, H., Arason,
285 A., Arndt, V., Aronson, K.J., Arun, B.K., et al. (2019). Genome-wide association and
286 transcriptome studies identify target genes and risk loci for breast cancer. *Nat Commun* 10,
287 1741.
- 288 8. Geeleher, P., Nath, A., Wang, F., Zhang, Z., Barbeira, A.N., Fessler, J., Grossman, R.L., Seoighe,
289 C., and Stephanie Huang, R. (2018). Cancer expression quantitative trait loci (eQTLs) can
290 be determined from heterogeneous tumor gene expression data by modeling variation in
291 tumor purity. *Genome Biol* 19, 130.
- 292 9. Plagnol, V., Smyth, D.J., Todd, J.A., and Clayton, D.G. (2009). Statistical independence of the
293 colocalized association signals for type 1 diabetes and RPS26 gene expression on
294 chromosome 12q13. *Biostatistics* 10, 327-334.
- 295 10. Giambartolomei, C., Vukcevic, D., Schadt, E.E., Franke, L., Hingorani, A.D., Wallace, C., and
296 Plagnol, V. (2014). Bayesian test for colocalisation between pairs of genetic association
297 studies using summary statistics. *PLoS Genet* 10, e1004383.
- 298 11. Parker, M.M., Hao, Y., Guo, F., Pham, B., Chase, R., Platig, J., Cho, M.H., Hersh, C.P.,
299 Thannickal, V.J., Crapo, J., et al. (2019). Identification of an emphysema-associated genetic
300 variant near TGFB2 with regulatory effects in lung fibroblasts. *Elife* 8.
- 301 12. Foley, C.N., Staley, J.R., Breen, P.G., Sun, B.B., Kirk, P.D.W., Burgess, S., and Howson, J.M.M.
302 (2019). A fast and efficient colocalization algorithm for identifying shared genetic risk factors
303 across multiple traits. bioRxiv doi: <https://doi.org/10.1101/592238>.
- 304 13. Thom, C.S., and Voight, B.F. (2020). Genetic colocalization atlas points to common regulatory
305 sites and genes for hematopoietic traits and hematopoietic contributions to disease
306 phenotypes. bioRxiv doi: <https://doi.org/10.1101/787333>.

- 307 14. Fachal, L., Aschard, H., Beesley, J., Barnes, D.R., Allen, J., Kar, S., Pooley, K.A., Dennis, J.,
308 Michailidou, K., Turman, C., et al. (2020). Fine-mapping of 150 breast cancer risk regions
309 identifies 191 likely target genes. *Nat Genet* 52, 56-73.
- 310 15. Milne, R.L., Kuchenbaecker, K.B., Michailidou, K., Beesley, J., Kar, S., Lindstrom, S., Hui, S.,
311 Lemacon, A., Soucy, P., Dennis, J., et al. (2017). Identification of ten variants associated with
312 risk of estrogen-receptor-negative breast cancer. *Nat Genet* 49, 1767-1778.
- 313 16. Barfield, R., Feng, H., Gusev, A., Wu, L., Zheng, W., Pasaniuc, B., and Kraft, P. (2018).
314 Transcriptome-wide association studies accounting for colocalization using Egger
315 regression. *Genet Epidemiol* 42, 418-433.
- 316 17. Feng, H., Gusev, A., Pasaniuc, B., Wu, L., Long, J., Abu-Full, Z., Aittomaki, K., Andrulis, I.L.,
317 Anton-Culver, H., Antoniou, A.C., et al. (2020). Transcriptome-wide association study of
318 breast cancer risk by estrogen-receptor status. *Genet Epidemiol*.
- 319 18. Beesley, J., Sivakumaran, H., Moradi Marjaneh, M., Lima, L.G., Hillman, K.M., Kaufmann, S.,
320 Tuano, N., Hussein, N., Ham, S., Mukhopadhyay, P., et al. (2020). Chromatin interactome
321 mapping at 139 independent breast cancer risk signals. *Genome Biol* 21, 8.
- 322 19. Ghossaini, M., Edwards, S.L., Michailidou, K., Nord, S., Cowper-Sal Lari, R., Desai, K., Kar, S.,
323 Hillman, K.M., Kaufmann, S., Glubb, D.M., et al. (2014). Evidence that breast cancer risk at
324 the 2q35 locus is mediated through IGFBP5 regulation. *Nat Commun* 4, 4999.
- 325 20. Ward, L.D., and Kellis, M. (2016). HaploReg v4: systematic mining of putative causal variants,
326 cell types, regulators and target genes for human complex traits and disease. *Nucleic Acids*
327 *Res* 44, D877-881.
- 328 21. Grabe, N. (2002). AliBaba2: context specific identification of transcription factor binding sites. In
329 *Silico Biol* 2, S1-15.
- 330 22. Wilson, B.D., Ii, M., Park, K.W., Suli, A., Sorensen, L.K., Larrieu-Lahargue, F., Urness, L.D., Suh,
331 W., Asai, J., Kock, G.A., et al. (2006). Netrins promote developmental and therapeutic
332 angiogenesis. *Science* 313, 640-644.
- 333 23. Lv, B., Song, C., Wu, L., Zhang, Q., Hou, D., Chen, P., Yu, S., Wang, Z., Chu, Y., Zhang, J., et
334 al. (2015). Netrin-4 as a biomarker promotes cell proliferation and invasion in gastric cancer.
335 *Oncotarget* 6, 9794-9806.

- 336 24. Jayachandran, A., Prithviraj, P., Lo, P.H., Walkiewicz, M., Anaka, M., Woods, B.L., Tan, B.,
337 Behren, A., Cebon, J., and McKeown, S.J. (2016). Identifying and targeting determinants of
338 melanoma cellular invasion. *Oncotarget* 7, 41186-41202.
- 339 25. Eveno, C., Broqueres-You, D., Feron, J.G., Rampanou, A., Tijeras-Raballand, A., Ropert, S.,
340 Leconte, L., Levy, B.I., and Pocard, M. (2011). Netrin-4 delays colorectal cancer
341 carcinomatosis by inhibiting tumor angiogenesis. *Am J Pathol* 178, 1861-1869.
- 342 26. Xu, X., Yan, Q., Wang, Y., and Dong, X. (2017). NTN4 is associated with breast cancer
343 metastasis via regulation of EMT-related biomarkers. *Oncol Rep* 37, 449-457.
- 344 27. Essegir, S., Reis-Filho, J.S., Kennedy, A., James, M., O'Hare, M.J., Jeffery, R., Poulsom, R.,
345 and Isacke, C.M. (2006). Identification of transmembrane proteins as potential prognostic
346 markers and therapeutic targets in breast cancer by a screen for signal sequence encoding
347 transcripts. *J Pathol* 210, 420-430.
- 348 28. Essegir, S., Kennedy, A., Seedhar, P., Nerurkar, A., Poulsom, R., Reis-Filho, J.S., and Isacke,
349 C.M. (2007). Identification of NTN4, TRA1, and STC2 as prognostic markers in breast cancer
350 in a screen for signal sequence encoding proteins. *Clin Cancer Res* 13, 3164-3173.
- 351 29. Betts, J.A., Moradi Marjaneh, M., Al-Ejeh, F., Lim, Y.C., Shi, W., Sivakumaran, H., Tropee, R.,
352 Patch, A.M., Clark, M.B., Bartonicek, N., et al. (2017). Long Noncoding RNAs CUPID1 and
353 CUPID2 Mediate Breast Cancer Risk at 11q13 by Modulating the Response to DNA Damage.
354 *Am J Hum Genet* 101, 255-266.
- 355 30. Visser, M., Kayser, M., and Palstra, R.J. (2012). HERC2 rs12913832 modulates human
356 pigmentation by attenuating chromatin-loop formation between a long-range enhancer and
357 the OCA2 promoter. *Genome Res* 22, 446-455.
- 358 31. Lin, Y., Ma, W., and Benchimol, S. (2000). Pidd, a new death-domain-containing protein, is
359 induced by p53 and promotes apoptosis. *Nat Genet* 26, 122-127.
- 360 32. Chung, C.Y., Sun, Z., Mullokandov, G., Bosch, A., Qadeer, Z.A., Cihan, E., Rapp, Z., Parsons,
361 R., Aguirre-Ghiso, J.A., Farias, E.F., et al. (2016). Cbx8 Acts Non-canonically with Wdr5 to
362 Promote Mammary Tumorigenesis. *Cell Rep* 16, 472-486.

- 363 33. Moradi Marjaneh, M., Beesley, J., O'Mara, T.A., Mukhopadhyay, P., Koufariotis, L.T., Kazakoff,
364 S., Hussein, N., Fachal, L., Bartonicek, N., Hillman, K.M., et al. (2020). Non-coding RNAs
365 underlie genetic predisposition to breast cancer. *Genome Biol* 21, 7.
- 366 34. Xu, S., Kong, D., Chen, Q., Ping, Y., and Pang, D. (2017). Oncogenic long noncoding RNA
367 landscape in breast cancer. *Mol Cancer* 16, 129.
- 368 35. Liu, B., Gloudemans, M.J., Rao, A.S., Ingelsson, E., and Montgomery, S.B. (2019). Abundant
369 associations with gene expression complicate GWAS follow-up. *Nat Genet* 51, 768-769.
- 370 36. Machiela, M.J., and Chanock, S.J. (2015). LDlink: a web-based application for exploring
371 population-specific haplotype structure and linking correlated alleles of possible functional
372 variants. *Bioinformatics* 31, 3555-3557.

373

374 **FIGURE LEGENDS**

375 **Figure 1. Comparison of association signals from BCAC and GTEx v8 for breast tissue.**

376 LocusCompare plots³⁵ for eleven high-probability colocalized signals. Gene names and the relevant
377 breast cancer phenotypes are shown in the plot headings. Points are coloured based on linkage
378 disequilibrium (LD) bins relative to the candidate SNP prioritized by HyPrColoc (purple diamond
379 labelled with rsID; red: ≥ 0.8 , orange: 0.6 – 0.8, green: 0.4 – 0.6, light blue: 0.2 – 0.4, and dark blue:
380 < 0.2). LD data from 1000 Genomes phase 3, version 5 were retrieved from the LDlink portal³⁶.
381 Strong candidate causal variants for breast cancer risk are annotated as small diamonds and weaker
382 secondary risk variants as squares.

383

384 **Figure 2. Regional association plots at the 12q22 breast cancer risk locus.**

385 Single variant associations with overall breast cancer risk (top panel) and with *NTN4* expression in normal breast
386 tissue from GTEx v8 (lower panel). Variants are represented by points colored relative to linkage
387 disequilibrium (LD) with the candidate variant detected by HyPrColoc (rs17356907; red: ≥ 0.8 ,
388 orange: 0.6 – 0.8, green: 0.4 – 0.6, light blue: 0.2 – 0.4, and dark blue: < 0.2).

389

390 **Figure 3. Breast cancer CCVs distally regulate *NTN4*.** (A) WashU genome browser showing

391 topologically associating domains (TADs) as horizontal gray bars above GENCODE annotated

392 coding genes (blue). The promoter capture Hi-C (PCHi-C) baits are depicted as black boxes. The
393 putative regulatory element (PRE) containing the CCVs is shown as red colored vertical lines. The
394 ATAC-seq tracks for B80T5 and MCF10A breast cells are shown as blue histograms. PCHi-C
395 chromatin interactions are shown as black arcs. Red arcs depict chromatin looping between CCVs
396 and the *NTN4* promoter region. (B) dCAS9-KRAB was targeted to the PRE using two different
397 sgRNAs (sgPRE1 and sgPRE2) in Bre80-TERT1 breast cells. SgCON contains a non-targeting
398 control guide RNA. Gene expression was measured by qPCR and normalized to *beta-glucuronidase*
399 (*GUSB*) expression. Error bars, SEM (n=3). *P*-values were determined by one-way ANOVA followed
400 by Dunnett's multiple comparisons test (**p < 0.01). (C) Luciferase reporter assays following
401 transient transfection of MCF10A and Bre80-TERT1 breast cells. A PRE1 containing the protective
402 (Prot.) or risk alleles of rs61938093 and a PRE2 containing the protective (Prot.) or risk alleles of
403 rs1735907 were cloned into *NTN4*-promoter driven luciferase constructs. Error bars, SEM (n=3). *P*-
404 values were determined by two-way ANOVA followed by Dunnett's multiple comparisons test (**p <
405 0.01, ****p < 0.0001). (D,E; left panels) 3C interaction profiles between the *NTN4* promoter and the
406 genomic region containing the PRE in MCF10A (D) and T47D (E) 3C libraries generated with HindIII.
407 A physical map of the region interrogated by 3C is shown above; the blue shading represents the
408 position of the PRE and the anchor point set at the *NTN4* promoter. Representative 3C profiles are
409 shown. Error bars, SD (n=3). (D,E; right panels) Allele-specific qPCR to quantify the allelic ratio at
410 CCV rs61938093. Error bars, SEM (n=3). *P*-values were determined using a Student's t-test (**p <
411 0.001). (F) EMSA for oligonucleotide duplexes containing CCVs rs61938093 or rs17356907 with
412 either the risk allele (R) or protective allele (P) as indicated, assayed using Bre80-TERT1 nuclear
413 extracts. Competitor oligonucleotides are listed above each panel and were used at 100-fold molar
414 excess: (-) no competitor; (Neg) a non-specific competitor; (Self) an identical oligonucleotide with no
415 biotin label. Red arrowheads indicate band mobility differences between alleles.

416

417 **Figure 4. *NTN4* depletion promotes breast cell proliferation and tumor formation.** (A) Boxplot
418 showing *NTN4* expression in normal breast and paired tumor tissue samples from TCGA. Boxplots
419 indicate median (centre line), interquartile range (box limits) and range (whiskers). *P*-value was
420 determined using a two-tailed t-test. (B) Boxplot showing *NTN4* expression in breast tumors from

421 TCGA stratified by PAM50 molecular subtypes (n=841). Boxplots indicate median (centre line),
422 interquartile range (box limits) and range (whiskers). **(C)** Proliferation of MCF7 cells transfected with
423 a non-targeting control (siCON) or *NTN4* (siNTN4) ON-TARGETplus siRNAs. Cells were grown in
424 24-well plates and confluency of the wells was measured by the IncuCyte live-cell imaging system.
425 Results represent relative cell growth rates. Error bars, SD (n=2). P-value was determined by
426 Student's t-test comparing confluency at the last time point measured (**p < 0.001). **(D)** MCF7 cells
427 were transfected with the siCON or siNTN4 and grown over 7 days in ultra low-attachment
428 conditions. Cell growth was assessed using the CellTiter-Glo luminescent cell viability assay. Graph
429 shows fold change in luminescence of siNTN4 treated cells relative to siCON treated cells. Error bar,
430 SEM (n=3). P-value was determined by Student's t-test test (**p < 0.01). **(E)** MCF7-control (PgCON)
431 or MCF7-dCas9-KRAB *NTN4* repressed cells (SgNTN4-P1/P2) were orthotopically injected into the
432 mammary fat pads of nude mice. Tumor growth curves for each group are shown. Values are shown
433 as average tumor volumes at each time point. Error bars, SEM (n=6-7 mice per group). **(F)** Tumors
434 of individual mice were dissected at day 38 post-injection. The scale bars represent 1 cm. **(G)** Plot
435 of the individual weights of tumors with mean and SEM shown by cross-bar and error bars. **(E, G)**
436 Mann-Whitney *U* test was used to compare differences between groups (*p < 0.05, **p < 0.01, ***p
437 < 0.001).

438 **Table 1.** Candidate breast cancer risk genes identified by eQTL colocalization analyses.
 439

Ensembl ID	Gene symbol	Breast cancer risk association	Genomic coordinates (hg19)	Posterior probability	Candidate SNP	Posterior explained by SNP	GTEx eQTL P value	Breast cancer risk P value
ENSG00000074527.11	<i>NTN4</i>	Overall risk	chr12:95527759-96527759	0.9466	rs17356907	0.97	8.01E-09	1.02E-39
ENSG00000141570.10	<i>CBX8</i>	Overall risk	chr17:77281387-78281725	0.9178	rs9905914	0.49	7.92E-23	4.00E-09
ENSG00000198945.7	<i>L3MBTL3</i>	Overall risk	chr6:129849119-130849119	0.7998	rs7740107	1.00	5.88E-40	2.90E-11
ENSG00000183654.8	<i>MARCH11</i>	Overall risk	chr5:15687358-16687528	0.8369	rs1013018	0.16	3.05E-09	1.65E-11
ENSG00000177595.17	<i>PIDD1</i>	Overall risk	chr11:303017-1303017	0.9695	rs6597981	0.22	6.53E-27	1.35E-12
ENSG00000166965.12	<i>RCCD1</i>	Overall risk	chr15:91009215-92009215	0.9633	rs113343095	0.60	2.44E-24	3.37E-15
ENSG00000130511.15	<i>SSBP4</i>	Overall risk	chr19:18050434-19071141	0.7800	rs7258465	0.09	7.87E-08	2.79E-28
ENSG00000172748.13	<i>ZNF596</i>	ER- risk	chr8:0-670692	0.9059	rs35346588	0.79	2.17E-08	1.39E-08
ENSG00000258725.1	<i>PRC1-AS1*</i>	Overall risk	chr15:91009215-92009215	0.9302	rs2290202	0.22	5.89E-10	1.87E-15
ENSG00000251141.5	<i>RP11-53019.1*</i>	Overall risk	chr5:44013304-45206498	0.9347	rs10941679	1.00	4.41E-07	5.61E-73
ENSG00000272812.1	<i>RP5-855D21.3*</i>	ER- risk	chr8:0-670692	0.9769	rs3008281	0.81	6.11E-08	6.23E-09
ENSG00000152348.15	<i>ATG10#</i>	Overall risk	chr5:80928261-82038046	0.7904	rs144580806	0.36	2.56E-40	8.07E-12
ENSG00000015133.18	<i>CCDC88C#</i>	Overall risk	chr14:91341069-92368623	0.9465	rs8018155	0.50	9.15E-11	4.03E-12
ENSG00000163644.14	<i>PPM1K#</i>	Overall risk	chr4:88743818-89743818	0.9935	rs10022462	0.58	1.60E-08	1.55E-09
ENSG00000233967.6	<i>RP11-250B2.3*#</i>	Overall risk	chr6:80594287-81594287	0.8473	rs9448940	0.22	4.65E-11	9.85E-09
ENSG00000260645.1	<i>RP11-250B2.5*#</i>	Overall risk	chr6:80594287-81594287	0.8227	rs1436864	0.08	1.97E-08	3.89E-09
ENSG00000219392.1	<i>RP1-265C24.5*#</i>	Overall risk	chr6:26180698-27180698	0.9901	rs35768595	0.38	5.95E-10	3.16E-09

440
 441 * Noncoding RNAs
 442 # Weaker secondary signals¹⁴
 443
 444
 445